Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto PortfolioQuarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer\n\n\n\n TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), is pleased to announce its financial and operational results for the third quarter ending September 30, 2025.\n \n\n The Company remains in a strong financial position. A quarter-over-quarter comparison of Q3 2025 with Q2 2025 highlights a period of significant strengthening, with a 275% increase in shareholder equity, an 86% reduction in the debt-to-equity ratio, a 50% decrease in total liabilities, primarily due to the elimination of all liabilities associated with the previously issued convertible debentures, and an 8% reduction in General and Administrative expenses. Year to date, the Company has realized gains of US$572,000 from its digital asset portfolio, which is comprised mainly of Bitcoin. The company reaffirms its “no going concern” status, and management believes that existing capital resources are sufficient to maintain operations beyond March 2027.\n \n\n Specifically, comparing Q3 2025 with Q2 2025, Quantum BioPharma has achieved:\n \n\n\n A 50% reduction in total liabilities, decreasing from US$13.2M to US$6.6M;\n \n\n\n\n A 275% increase in shareholder equity, increasing from US$2M up to US$7.5M , as a direct result of the above decrease in liabilities;\n \n\n\n\n An 87% reduction in the Company’s debt-to-equity ratio, improving from a highly leveraged 6.47x to a strong and sustainable 0.89x;\n \n\n\n\n A 40 percentage point increase in the equity to total assets ratio, from 13% to 53%, indicating that the Company's assets are now predominantly financed by equity rather than debt; and\n \n\n\n\n A significant improvement in liquidity, as evidenced by the current ratio increasing from 0.78x to 1.41x, further demonstrating the Company's ability to cover its short-term obligations.\n \n\n\n\n\n\n Strong Third Quarter Financial...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B